Shennon Biotechnologies

San Francisco, United States Founded: 2021 • Age: 5 yrs
Developer of immune cell therapies against solid tumors and autoimmune disease

About Shennon Biotechnologies

Shennon Biotechnologies is a Healthcare company based in San Francisco (United States) founded in 2021. Developer of immune cell therapies against solid tumors and autoimmune disease. Shennon Biotechnologies has raised $25 million across 2 funding rounds from investors including Foundation Capital, AV8 Ventures and DCVC. Shennon Biotechnologies offers products and services including Single Cell Platform. Its focus areas include Life Sciences, Immunotherapy, Diversified and Oncology. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.

Company details

Shennon Biotechnologies was established in 2021 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, where immune cell therapies are developed to address solid tumors and autoimmune diseases. Operations involve research and development of these therapies, with activities conducted primarily in the United States. The companys domain, shennonbio.com, supports its online presence in the field.

Key Metrics
  • Total Equity Funding
    $25M (USD)

    in 2 rounds

  • Latest Funding Round
    $12M (USD), Seed

    Sep 2026

  • Investors

Products & Services of Shennon Biotechnologies

Shennon Biotechnologies offers a comprehensive portfolio of products and services, including Single Cell Platform.

Single Cell Platform
Biotech Tool

Profiles millions of immune cells to identify targets for therapies.

Funding Insights of Shennon Biotechnologies

Shennon Biotechnologies has successfully raised a total of $25M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $12 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $25M
  • Total Rounds 2
  • Last Round Seed β€” $12M
  • First Round $13M

    (Mar 2023)

  • Investors Count 8

All 2 funding rounds of Shennon Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2026$12MSeed––
Mar 2023$13MSeed–DCVC
Valuation history

8 investors in total: 8 institutional.

Investors in Shennon Biotechnologies

Shennon Biotechnologies has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Foundation Capital, AV8 Ventures and DCVC.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on early-stage fintech, enterprise, web 3, consumer, and multiple sectors
1995foundationcapital.comPalo Alto, United States
Early-stage startups are supported by AV8 Ventures through investments.
2021av8.vcPalo Alto, United States
Venture capital firm focused on multiple sectors
dcvc.comPalo Alto, United States
future.ventures
nextgenvp.com
samos.vc
atypical.com
sarascapital.com
Premium access

Investor details for Shennon Biotechnologies

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Shennon Biotechnologies

3 dated milestones of Shennon Biotechnologies across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Shennon Biotechnologies is founded.
  2. Funding First funding round of $13.0M.
  3. Funding Latest funding round, Seed, of $12.0M.

Competitors of Shennon Biotechnologies

Shennon Biotechnologies has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
incyte.com1991Wilmington, United States1,387
Small molecules are developed for cancer and skin disease treatments.
Premium access

Detailed competitors of Shennon Biotechnologies

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Shennon Biotechnologies

Websites that share an audience with Shennon Biotechnologies (shennonbio.com).

Similar websites

Websites whose visitors overlap most with Shennon Biotechnologies. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
r2mpharma.com
100%
2.9K#4,331,217View details
aligos.com
100%
3.4K#3,982,602View details
quantatx.com
100%
3.1K#5,909,422View details
excision.bio
99%
2.4K#7,581,873View details
astellasgenetherapies.com
98%
1KView details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 27 similar websites and full traffic analytics for Shennon Biotechnologies

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 27 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Shennon Biotechnologies (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Shennon Biotechnologies

Premium access

Complete news archive for Shennon Biotechnologies

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shennon Biotechnologies

Shennon Biotechnologies was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Shennon Biotechnologies is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Shennon Biotechnologies is a funded company, having raised a total of $25M across 2 funding rounds to date. The company's 1st funding round was a Seed of $13M, raised on Mar 2023.

Shennon Biotechnologies was established in 2021 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, where immune cell therapies are developed to address solid tumors and autoimmune diseases. Operations involve research and development of these therapies, with activities conducted primarily in the United States. The companys domain, shennonbio.com, supports its online presence in the field.

Shennon Biotechnologies's top competitors include Moderna, BeiGene and Incyte.

Shennon Biotechnologies offers Single Cell Platform.

Shennon Biotechnologies has 8 investors. Key investors include Foundation Capital, AV8 Ventures, DCVC, Future Ventures, and NextGen Venture Partners.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available